Literature DB >> 8547873

Transplantation of allogeneic rhG-CSF mobilized peripheral CD34+ cells from an HLA-identical unrelated donor.

M Stockschläder1, C Löliger, W Krüger, W Zeller, A Heyll, P Schönrock-Nabulsi, A Zander.   

Abstract

We describe the case of a 41-year-old female who underwent allogeneic blood cell transplantation with CD34(+)-enriched cells from an HLA-matched unrelated donor for AML in second CR. The conditioning regimen consisted of TBI (12 Gy), VP16 (1800 mg), cyclophosphamide (7200 mg), and ATG (7200 mg). GVHD prophylaxis consisted of CsA and a short course of MTX. Receiving G-CSF from day +1, engraftment occurred on day +19 after stem cell infusion. Starting on day +10, GVHD grade II (skin and liver) developed that responded to high-dose steroid therapy. The patient died on day +38 due to suspected cerebral aspergillus infection. This case demonstrates the feasibility of primary transplantation of CD34(+)-enriched allogeneic peripheral stem cells from a matched unrelated donor leading to engraftment of donor cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8547873

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  3 in total

1.  Short-term cryopreservation of allogeneic stem cells for optimization of transplant conditions in children.

Authors:  Petra Sovinz; Wolfgang Schwinger; Herwig Lackner; Andrea Nebl; Sabine Sipurzynski; Christian Urban
Journal:  Haematologica       Date:  2010-04-30       Impact factor: 9.941

Review 2.  Bone marrow transplantation using unrelated donors for haematological malignancies.

Authors:  O Ringdén
Journal:  Med Oncol       Date:  1997-03       Impact factor: 3.064

3.  Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center study.

Authors:  I W Blau; N Basara; G Lentini; S Guenzelmann; D Kirsten; B Schmetzer; M Bischoff; E Roemer; M G Kiehl; A A Fauser
Journal:  Bone Marrow Transplant       Date:  2001-01       Impact factor: 5.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.